This is a snippet of the transcript, sign up to read more.
When Mars makes an acquisition like this, there is an expectation that everything integrates into their ecosystem. However, there are some long-term contracts with Banfield and BluePearl, which means we can conduct business relatively quickly with our emergency analyzer. When Mars makes an acquisition, they aim for vertical integration, but this requires internal negotiations on transfer prices and financial terms. It's not as simple as just buying Heska and having their clinics use it. Instead, there needs to be an agreement. Eventually, I guarantee that Heska will be in all Mars veterinary hospitals. Currently, this hasn't happened yet due to long-term deals and ongoing internal negotiations on pricing. The expectation is that Heska will be part of every hospital within the Mars ecosystem.
This is a snippet of the transcript, sign up to read more.
We often lost deals because we didn't have a full stack. Not having a reference lab was an issue. Unlike IDEXX, which did a really good job with SDMA, which is available on the Catalyst for Heska analyzers, they made that a main component. Not having that particular parameter was problematic. Integration is often an issue. IDEXX has done a phenomenal job as a company, whereas we at Heska didn't integrate with all systems. I know that Antech is currently working on that. Integration is crucial for the workflow of a practice, and if you do not integrate, it becomes an issue.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research